Melanoma genotypes and phenotypes get personal

Laboratory Investigation

Volumn 93, Issue 8, 2013, Pages 858-867

  Pimiento, Jose M ^a,b,c   Larkin, Eileen M ^c   Smalley, Keiran Sm ^d   Wiersma, Ginger L ^c   Monks, Noel R ^b   Fedorenko, Inna V ^d   Peterson, Chelsea A ^c   Nickoloff, Brian J ^a,b,c  

^a Saint Mary's Health Care   (United States)

^b VAN ANDEL INSTITUTE   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

BRAF; Genomics; Immunotherapy; MAPK signaling; Patient derived tumorgrafts; Personalized medicine; Vemurafenib

Indexed keywords

B RAF KINASE; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STEM CELL; CELL PROLIFERATION; CHILDHOOD CANCER; CLINICAL PROTOCOL; EXOSOME; GENE MUTATION; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; IMMUNITY; MELANOCYTE; MELANOMA; MELANOMA CELL; MOLECULAR GENETICS; NEURAL CREST; NONHUMAN; NONSENSE MUTATION; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; SUN EXPOSURE; SUNLIGHT; TUMOR CLASSIFICATION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

EID: 84881034188     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2013.84     Document Type: Review

References (117)

1. Menendez L, Kulik MJ, Page AT, et al. Directed differentiation of human pluripotent cells to neural crest stem cells. Nat Protoc 2013;8: 203-212.
2. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33: 19-20.
3. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-954.
4. Bauer J, Curtin JA, Pinkel D, et al. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol 2007;127: 179-182.
5. Kinsler VA, Thomas AC, Ishida M, et al. Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. J Invest Dermatol; advance online publication, 7 February 2013; doi: 10.1038/jid.2013.70 (e-pub ahead of print).
6. Pedersen M, Kusters-Vandevelde HV, Viros A, et al. Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes. Cancer Discov 2013;3: 458-469.
7. Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011;43: 1018-1021.
8. Busam KJ, Sung J, Wiesner T, et al. Combined BRAF(V600E)-positive melanocytic lesions with large epithelioid cells lacking BAP1 expression and conventional nevomelanocytes. Am J Surg Pathol 2013;37: 193-199.
9. Krengel S, Scope A, Dusza SW, et al. New recommendations for the categorization of cutaneous features of congenital melanocytic nevi. J Am Acad Dermatol 2013;68: 441-451.
10. Berwick M, Orlow I, Hummer AJ, et al. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev 2006;15: 1520-1525.
11. Jonsson A, Tuominen R, Grafstrom E, et al. High frequency of p16 (INK4A) promoter methylation in NRAS-mutated cutaneous melanoma. J Invest Dermatol 2010;130: 2809-2817.
12. Jenkins NC, Liu T, Cassidy P, et al. The p16(INK4A) tumor suppressor regulates cellular oxidative stress. Oncogene 2011;30: 265-274.
13. Mitra D, Luo X, Morgan A, et al. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 2012;491: 449-453.
14. Zaidi MR, De Fabo EC, Noonan FP, et al. Shedding light on melanocyte pathobiology in vivo. Cancer Res 2012;72: 1591-1595.
15. Chu CC, Ali N, Karagiannis P, et al. Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. J Exp Med 2012; 209: 935-945.
16. Huang FW, Hodis E, Xu MJ, et al. Highly recurrent TERT promoter mutations in human melanoma. Science 2013;339: 957-959.
17. Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013;339: 959-961.
18. Rass K, Reichrath J. UV damage and DNA repair in malignant melanoma and nonmelanoma skin cancer. In: Reichrath J (ed) Sunlight, Vitamin D and Skin Cancer, New York, NY, USA, 2008 162-178.
19. Berger MF, Hodis E, Heffernan TP, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012;485: 502-506.
20. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010;463: 191-196.
21. Krzywinski M, Schein J, Birol I, et al. Circos: an information aesthetic for comparative genomics. Genome Res 2009;19: 1639-1645.
22. Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011;3: 111ra21.
23. Mehnert JM, Kluger HM. Driver mutations in melanoma: lessons learned from bench-to-bedside studies. Curr Oncol Rep 2012;14: 449-457.
24. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell 2012;150: 251-263.
25. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318: 1108-1113.
26. Tsao H, Chin L, Garraway LA, et al. Melanoma: from mutations to medicine. Genes Dev 2012;26: 1131-1155.
27. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 2012;12: 349-361.
28. McArthur GA. The coming of age of MEK. Lancet Oncol 2012;13: 744-745.
29. Hearing VJ, Leong SPL. From melanocytes to melanoma: the progression to malignancy. In: Human Press Incorporated, 2006.
30. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410: 37-40.
31. Leong SP, Mihm Jr MC, Murphy GF, et al. Progression of cutaneous melanoma: implications for treatment. Clin Exp Metastasis 2012; 29: 775-796.
32. McArthur GA, Ribas A. Targeting oncogenic drivers and the immune system in melanoma. J Clin Oncol 2013;31: 499-506.
33. Holzel M, Bovier A, Tuting T. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer 2013;13: 365-376.
34. Anvekar RA, Asciolla JJ, Missert DJ, et al. Born to be alive: a role for the BCL-2 family in melanoma tumor cell survival, apoptosis, and treatment. Front Oncol 2011;1: 34; advance online publication, 13 October 2011; doi: 10.3389/fonc.2011.00034.
35. Vidwans SJ, Flaherty KT, Fisher DE, et al. A melanoma molecular disease model. PLoS One 2011;6: e18257.
36. Swick JM, Maize Sr JC. Molecular biology of melanoma. J Am Acad Dermatol 2012;67: 1049-1054.
37. Takata M, Saida T. Genetic alterations in melanocytic tumors. J Dermatol Sci 2006;43: 1-10.
38. Sullivan RJ, Flaherty K. MAP kinase signaling and inhibition in melanoma. Oncogene 2013;32: 2373-2379.
39. Tsao H, Goel V, Wu H, et al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004;122: 337-341.
40. Goel VK, Lazar AJ, Warneke CL, et al. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 2006;126: 154-160.
41. Govindarajan B, Sligh JE, Vincent BJ, et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 2007;117: 719-729.
42. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457: 599-602.
43. Fisher DE, Barnhill R, Hodi FS, et al. Melanoma from bench to bedside: meeting report from the 6th international melanoma congress. Pigment Cell Melanoma Res 2010;23: 14-26.
44. Maertens O, Johnson B, Hollstein P, et al. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov 2013;3: 338-349.
45. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353: 2135-2147.
46. Edlundh-Rose E, Egyhazi S, Omholt K, et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 2006;16: 471-478.
47. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24: 4340-4346.
48. Woodman SE, Davies MA. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 2010;80: 568-574.
49. Ashida A, Takata M, Murata H, et al. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer 2009;124: 862-868.
50. Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14: 6821-6828.
51. Garrido MC, Bastian BC. KIT as a therapeutic target in melanoma. J Invest Dermatol 2010;130: 20-27.
52. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Revi Cancer 2012;12: 349-361.
53. Cartlidge RA, Thomas GR, Cagnol S, et al. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res 2008;21: 534-544.
54. Lito P, Pratilas CA, Joseph EW, et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012;22: 668-682.
55. Miller AJ, Mihm Jr MC. Melanoma. N Engl J Med 2006;355: 51-65.
56. Topczewska JM, Postovit LM, Margaryan NV, et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med 2006;12: 925-932.
57. McAllister JC, Zhan Q, Weishaupt C, et al. The embryonic morphogen, Nodal, is associated with channel-like structures in human malignant melanoma xenografts. J Cut Pathol 2010;37(Suppl 1): 19-25.
58. Girouard SD, Murphy GF. Melanoma stem cells: not rare, but well done. Lab Invest 2011;91: 647-664.
59. Hoek KS, Goding CR. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res 2010;23: 746-759.
60. Lang D, Mascarenhas JB, Shea CR. Melanocytes melanocyte stem cells, and melanoma stem cells. Clin Dermatol 2013;31: 166-178.
61. Lee JT, Herlyn M. Microenvironmental influences in melanoma progression. J Cell Biochem 2007;101: 862-872.
62. Fidler IJ, Poste G. The "seed and soil" hypothesis revisited. Lancet Oncol 2008;9: 808.
63. Raz A, Ben-Ze'ev A. Modulation of the metastatic capability in B16 melanoma by cell shape. Science 1983;221: 1307-1310.
64. Houben R, Vetter-Kauczok CS, Ortmann S, et al. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. J Invest Dermatol 2008;128: 2003-2012.
65. Navin N, Kendall J, Troge J, et al. Tumour evolution inferred by singlecell sequencing. Nature 2011;472: 90-94.
66. Somasundaram R, Villanueva J, Herlyn M. Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Adv Pharmacol 2012;65: 335-359.
67. Hood JL, San RS, Wickline SA. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res 2011;71: 3792-3801.
68. Peinado H, Aleckovic M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012;18: 883-891.
69. Ferris LK, Harris RJ. New diagnostic aids for melanoma. Dermatol Clin 2012;30: 535-545.
70. Wachsman W, Morhenn V, Palmer T, et al. Noninvasive genomic detection of melanoma. Br J Dermatol 2011;164: 797-806.
71. Shoo BA, Sagebiel RW, Kashani-Sabet M. Discordance in the histopathologic diagnosis of melanoma at a melanoma referral center. J Am Acad Dermatol 2010;62: 751-756.
72. North JP, Vetto JT, Murali R, et al. Assessment of copy number status of chromosomes 6 and 11 by FISH provides independent prognostic information in primary melanoma. Am J Surg Pathol 2011;35: 1146-1150.
73. Wolman SR. Applications of fluorescence in situ hybridization techniques in cytopathology. Cancer 1997;81: 193-197.
74. Leong SP, Mihm Jr MC, Murphy GF, et al. Progression of cutaneous melanoma: implications for treatment. Clin Exp Metastasis 2012;29: 775-796.
75. Greenberg ES, Chong KK, Huynh KT, et al. Epigenetic biomarkers in skin cancer. Cancer Lett 2012 (in press).
76. Lian CG, Xu Y, Ceol C, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012;150: 1135-1146.
77. Shao Y, Aplin AE. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. Cell Death Differ 2012;19: 2029-2039.
78. Lai F, Jin L, Gallagher S, et al. Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors. Adv Pharmacol 2012;65: 27-43.
79. Hoshimoto S, Kuo CT, Chong KK, et al. AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Invest Dermatol 2012;132: 1689-1697.
80. Tanemura A, Terando AM, Sim MS, et al. CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 2009;15: 1801-1807.
81. Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006;24: 268-273.
82. Nguyen T, Kuo C, Nicholl MB, et al. Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics 2011;6: 388-394.
83. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 2013;37: 61-65.
84. Smalley KS, Sondak VK. Melanoma - an unlikely poster child for personalized cancer therapy. N Engl J Med 2010;363: 876-878.
85. Kwong LN, Davies MA. Targeted therapy for melanoma: rational combinatorial approaches. Oncogene; advance online publication, 18 February 2013; doi: 10.1038/onc.2013.34 (e-pub ahead of print).
86. Stewart DJ, Kurzrock R. Cancer: the road to Amiens. J Clin Oncol 2009;27: 328-333.
87. Kaiser J. Profile: Bert Vogelstein. Cancer genetics with an edge. Science 2012;337: 282-284.
88. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293: 876-880.
89. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2: e73.
90. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol 2013;14: e60-e69.
91. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamouscell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366: 207-215.
92. Akinleye A, Furqan M, Mukhi N, et al. MEK and the inhibitors: from bench to bedside. J Hematol Oncol 2013;6: 27.
93. McArthur GA. The coming of age of MEK. Lancet Oncol 2012;13: 744-745.
94. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Eng J Med 2012;367: 1694-1703.
95. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Eng J Med 2010;363: 711-723.
96. Ellis LM, Fidler IJ. Finding the tumor copycat. Therapy fails, patients don't. Nat Med 2010;16: 974-975.
97. Merlino G, Flaherty K, Acquavella N, et al. Meeting report: the future of preclinical mouse models in melanoma treatment is now. Pigment Cell Melanoma Res; advance online publication, 27 March 2013; doi: 10.1111/pcmr.12099 (e-pub ahead of print).
98. Li L, Fukunaga-Kalabis M, Herlyn M. The three-dimensional human skin reconstruct model: a tool to study normal skin and melanoma progression. J Vis Exp 2011;54: e2937.
99. Walker GJ, Soyer HP, Terzian T, et al. Modelling melanoma in mice. Pigment Cell Melanoma Res 2011;24: 1158-1176.
100. Juhasz I, Albelda SM, Elder DE, et al. Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am J Pathol 1993;143: 528-537.
101. Hidalgo M, Bruckheimer E, Rajeshkumar NV, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011;10: 1311-1316.
102. Monsma DJ, Monks NR, Cherba DM, et al. Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. J Transl Med 2012;10: 125.
103. Das Thakur M, Salangsang F, Landman AS, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013;494: 251-255.
104. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol 2007;7: 118-130.
105. Pavlin D, Cemazar M, Sersa G, et al. IL-12 based gene therapy in veterinary medicine. J Transl Med 2012;10: 234.
106. Ramos-Vara JA, Beissenherz ME, Miller MA, et al. Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases. Vet Pathol 2000;37: 597-608.
107. MacGillivray KC, Sweeney RW, Del Piero F. Metastatic melanoma in horses. J Vet Intern Med 2002;16: 452-456.
108. Seltenhammer MH, Heere-Ress E, Brandt S, et al. Comparative histopathology of grey-horse-melanoma and human malignant melanoma. Pigment Cell Res 2004;17: 674-681.
109. Morris EJ, Jha S, Restino CR, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov; advance online publication, 24 April 2013; CD-13-0070.
110. Leary RJ, Sausen M, Kinde I, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 2012;4162ra54.
111. Balk SJ, Fisher DE, Geller AC. Teens and indoor tanning: a cancer prevention opportunity for pediatricians. Pediatrics 2013;131: 772-785.
112. Berman DM, Bosenberg MW, Orwant RL, et al. Investigative pathology: leading the post-genomic revolution. Lab Invest 2012;92: 4-8.
113. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013; 137: 828-860.
114. Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013;19: 1225-1231.
115. Menaa F. Latest approved therapies for metastatic melanoma: what comes next? J Skin Cancer 2013;2013: 735282.
116. Kudchadkar RR, Smalley KS, Glass LF, et al. Targeted therapy in melanoma. Clin Dermatol 2013;31: 200-208.
117. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science 2013;339: 1546-1558.